2026 Q1 -tulosraportti
75 päivää sitten
‧24 min
0,15 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 3.2. | ||
2025 Q3 -tulosraportti 21.10.2025 | ||
2025 Q2 -tulosraportti 22.7.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·23.6.A bit wild that there are only approx 30% shares in free float, as Demant and Atp+ 2 funds own the remaining 70%, so it can quickly go north when the market eventually becomes rational again, since Embla is market-leading and has promised growth going forward.
The market is rational and always right. How Embla is priced can, however, change over time.- ·20.5.Perhaps someone can explain why this small growth stock has been beaten back 10 years in price! Every day Embla is held down, despite a large buyback program, and very good future prospects from management! I may be naive but I have supplemented a lot both in my pension and free funds at Saxo, as this in my eyes is a great investment with very little risk versus upside at these levels
The entire MedTech sector is negatively impacted by exposure to the USA, which is typically 50% for this type of company. This includes tariffs, USD headwinds, doubt/reduction of US subsidies on US Medicare/MedicAid, sector shift from Healthcare, as well as historically low growth expectations within MedTech. Multiples have come down 30-40% compared to 5 years ago. That being said, many analysts expect a turnaround is around the corner given that expectations are low with opportunities for upward revisions in the sector. 
·3.5.https://borsen.dk/news/companies/danish-controlled-prosthesis-group-sees-billion-market-in-ukraine's-war-invalids?b_source=borsen&b_medium=row_11&b_campaign=news_3
Unfortunately, there is probably a very great need for Embla's products in Ukraine. The question is whether an effective support scheme can be financed. These are, after all, very expensive products by Ukrainian standards. Russia is, in principle, in the same situation, but it will probably be a more difficult market to access even if the war ends one day.
·15.4.What do you think about this AI-generated analysis of Embla Medical based on Løgstrup's 3-phase model? Phase 1: Strategic Analysis Product: Embla is a global leader in bionic prostheses (AI-controlled legs and feet). They deliver life-changing technology that is difficult to copy. Market: The market is growing due to demographic changes (more elderly and lifestyle diseases like diabetes, which lead to amputations). Unfortunately, the Ukraine conflict has created a massive, long-term need for their services. Margins: The gross margin is high, but the EBITDA margin has been under pressure due to tariffs in the USA. The goal, however, is an increase towards 20-22% in 2026/27. Growth: Stable organic growth of 7-9% annually, supplemented by strategic acquisitions (especially clinics in the USA). Competition/Alternatives: Ottobock is the only real peer competitor. Phase 2: Return Calculation Jens Løgstrup focuses here on the relationship between earnings and price (P/E) as well as the return on invested capital. P/E ratio: As your own graphs showed, the P/E is expected to fall from high levels (around 21) to around 14-16 towards 2028. For a high-tech medical company, it is cheap for quality. ROIC (Return on Capital): Currently around 7.8% (2025), but expected to climb towards 9-10%. Løgstrup often prefers slightly higher figures, but accepts lower returns if growth is stable and capital is reinvested wisely. EPS growth: An expected annual increase in earnings per share of approx. 13-15% makes the stock appear fundamentally undervalued today. Phase 3: Qualitative Assessment Low investment level: Here Embla deviates, as bionics requires ongoing R&D (approx. 5% of revenue). Mergers/Acquisitions: Embla makes "bolt-on" acquisitions, where they buy smaller clinics and roll out their own technology in them (synergy effect). Løgstrup is mostly against large "headless" acquisitions, where a company buys a competitor that is almost as large as themselves. It is part of their core strategy to own the entire value chain. Stable management: The company is known for very experienced management with a long-term perspective, supported by the ultra-conservative main owner, William Demant Invest. High distribution: Embla does not pay high dividends, but instead uses share buybacks. Løgstrup often sees buybacks as a "tax-efficient dividend payment", especially when the price is low. Focused company: Yes, they do only one thing: Mobility solutions. No "diworsification". Among the best: They are undisputed top-2 in the world. Low risk during economic downturn: Here Embla scores top marks. People do not stop needing prostheses just because there is a crisis. It is a defensive growth stock. Conclusion: Embla Medical meets most of his criteria: It is a focused market leader in a defensive industry, currently trading at a reasonable price due to temporary headwinds (tariffs/currency).It's a good analysis that also reflects why I own the stock. Furthermore, Embla expects 5-7% organic growth and not 7-9% as stated in the analysis. That makes a big difference in the valuation. There are some seemingly very stable shareholders in the company, including demant holding and ATP, and the share of institutional investors is around 71%. This also means that there are relatively few private investors in the stock, which can also be seen from the interest here. It should make the share buyback program more effective that so many shares are held stably by the large investors, but unfortunately, the program is so small that the effect is probably limited. By the way, I don't think Løgstrup himself owns the stock. He seems to be focused on stocks with lower PE, such as banks, ISS, etc.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
75 päivää sitten
‧24 min
0,15 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23.6.A bit wild that there are only approx 30% shares in free float, as Demant and Atp+ 2 funds own the remaining 70%, so it can quickly go north when the market eventually becomes rational again, since Embla is market-leading and has promised growth going forward.The market is rational and always right. How Embla is priced can, however, change over time.
- ·20.5.Perhaps someone can explain why this small growth stock has been beaten back 10 years in price! Every day Embla is held down, despite a large buyback program, and very good future prospects from management! I may be naive but I have supplemented a lot both in my pension and free funds at Saxo, as this in my eyes is a great investment with very little risk versus upside at these levelsThe entire MedTech sector is negatively impacted by exposure to the USA, which is typically 50% for this type of company. This includes tariffs, USD headwinds, doubt/reduction of US subsidies on US Medicare/MedicAid, sector shift from Healthcare, as well as historically low growth expectations within MedTech. Multiples have come down 30-40% compared to 5 years ago. That being said, many analysts expect a turnaround is around the corner given that expectations are low with opportunities for upward revisions in the sector.
- ·3.5.https://borsen.dk/news/companies/danish-controlled-prosthesis-group-sees-billion-market-in-ukraine's-war-invalids?b_source=borsen&b_medium=row_11&b_campaign=news_3Unfortunately, there is probably a very great need for Embla's products in Ukraine. The question is whether an effective support scheme can be financed. These are, after all, very expensive products by Ukrainian standards. Russia is, in principle, in the same situation, but it will probably be a more difficult market to access even if the war ends one day.
- ·15.4.What do you think about this AI-generated analysis of Embla Medical based on Løgstrup's 3-phase model? Phase 1: Strategic Analysis Product: Embla is a global leader in bionic prostheses (AI-controlled legs and feet). They deliver life-changing technology that is difficult to copy. Market: The market is growing due to demographic changes (more elderly and lifestyle diseases like diabetes, which lead to amputations). Unfortunately, the Ukraine conflict has created a massive, long-term need for their services. Margins: The gross margin is high, but the EBITDA margin has been under pressure due to tariffs in the USA. The goal, however, is an increase towards 20-22% in 2026/27. Growth: Stable organic growth of 7-9% annually, supplemented by strategic acquisitions (especially clinics in the USA). Competition/Alternatives: Ottobock is the only real peer competitor. Phase 2: Return Calculation Jens Løgstrup focuses here on the relationship between earnings and price (P/E) as well as the return on invested capital. P/E ratio: As your own graphs showed, the P/E is expected to fall from high levels (around 21) to around 14-16 towards 2028. For a high-tech medical company, it is cheap for quality. ROIC (Return on Capital): Currently around 7.8% (2025), but expected to climb towards 9-10%. Løgstrup often prefers slightly higher figures, but accepts lower returns if growth is stable and capital is reinvested wisely. EPS growth: An expected annual increase in earnings per share of approx. 13-15% makes the stock appear fundamentally undervalued today. Phase 3: Qualitative Assessment Low investment level: Here Embla deviates, as bionics requires ongoing R&D (approx. 5% of revenue). Mergers/Acquisitions: Embla makes "bolt-on" acquisitions, where they buy smaller clinics and roll out their own technology in them (synergy effect). Løgstrup is mostly against large "headless" acquisitions, where a company buys a competitor that is almost as large as themselves. It is part of their core strategy to own the entire value chain. Stable management: The company is known for very experienced management with a long-term perspective, supported by the ultra-conservative main owner, William Demant Invest. High distribution: Embla does not pay high dividends, but instead uses share buybacks. Løgstrup often sees buybacks as a "tax-efficient dividend payment", especially when the price is low. Focused company: Yes, they do only one thing: Mobility solutions. No "diworsification". Among the best: They are undisputed top-2 in the world. Low risk during economic downturn: Here Embla scores top marks. People do not stop needing prostheses just because there is a crisis. It is a defensive growth stock. Conclusion: Embla Medical meets most of his criteria: It is a focused market leader in a defensive industry, currently trading at a reasonable price due to temporary headwinds (tariffs/currency).It's a good analysis that also reflects why I own the stock. Furthermore, Embla expects 5-7% organic growth and not 7-9% as stated in the analysis. That makes a big difference in the valuation. There are some seemingly very stable shareholders in the company, including demant holding and ATP, and the share of institutional investors is around 71%. This also means that there are relatively few private investors in the stock, which can also be seen from the interest here. It should make the share buyback program more effective that so many shares are held stably by the large investors, but unfortunately, the program is so small that the effect is probably limited. By the way, I don't think Løgstrup himself owns the stock. He seems to be focused on stocks with lower PE, such as banks, ISS, etc.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 3.2. | ||
2025 Q3 -tulosraportti 21.10.2025 | ||
2025 Q2 -tulosraportti 22.7.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
2026 Q1 -tulosraportti
75 päivää sitten
‧24 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 28.4. | ||
2025 Q4 -tulosraportti 3.2. | ||
2025 Q3 -tulosraportti 21.10.2025 | ||
2025 Q2 -tulosraportti 22.7.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
0,15 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23.6.A bit wild that there are only approx 30% shares in free float, as Demant and Atp+ 2 funds own the remaining 70%, so it can quickly go north when the market eventually becomes rational again, since Embla is market-leading and has promised growth going forward.The market is rational and always right. How Embla is priced can, however, change over time.
- ·20.5.Perhaps someone can explain why this small growth stock has been beaten back 10 years in price! Every day Embla is held down, despite a large buyback program, and very good future prospects from management! I may be naive but I have supplemented a lot both in my pension and free funds at Saxo, as this in my eyes is a great investment with very little risk versus upside at these levelsThe entire MedTech sector is negatively impacted by exposure to the USA, which is typically 50% for this type of company. This includes tariffs, USD headwinds, doubt/reduction of US subsidies on US Medicare/MedicAid, sector shift from Healthcare, as well as historically low growth expectations within MedTech. Multiples have come down 30-40% compared to 5 years ago. That being said, many analysts expect a turnaround is around the corner given that expectations are low with opportunities for upward revisions in the sector.
- ·3.5.https://borsen.dk/news/companies/danish-controlled-prosthesis-group-sees-billion-market-in-ukraine's-war-invalids?b_source=borsen&b_medium=row_11&b_campaign=news_3Unfortunately, there is probably a very great need for Embla's products in Ukraine. The question is whether an effective support scheme can be financed. These are, after all, very expensive products by Ukrainian standards. Russia is, in principle, in the same situation, but it will probably be a more difficult market to access even if the war ends one day.
- ·15.4.What do you think about this AI-generated analysis of Embla Medical based on Løgstrup's 3-phase model? Phase 1: Strategic Analysis Product: Embla is a global leader in bionic prostheses (AI-controlled legs and feet). They deliver life-changing technology that is difficult to copy. Market: The market is growing due to demographic changes (more elderly and lifestyle diseases like diabetes, which lead to amputations). Unfortunately, the Ukraine conflict has created a massive, long-term need for their services. Margins: The gross margin is high, but the EBITDA margin has been under pressure due to tariffs in the USA. The goal, however, is an increase towards 20-22% in 2026/27. Growth: Stable organic growth of 7-9% annually, supplemented by strategic acquisitions (especially clinics in the USA). Competition/Alternatives: Ottobock is the only real peer competitor. Phase 2: Return Calculation Jens Løgstrup focuses here on the relationship between earnings and price (P/E) as well as the return on invested capital. P/E ratio: As your own graphs showed, the P/E is expected to fall from high levels (around 21) to around 14-16 towards 2028. For a high-tech medical company, it is cheap for quality. ROIC (Return on Capital): Currently around 7.8% (2025), but expected to climb towards 9-10%. Løgstrup often prefers slightly higher figures, but accepts lower returns if growth is stable and capital is reinvested wisely. EPS growth: An expected annual increase in earnings per share of approx. 13-15% makes the stock appear fundamentally undervalued today. Phase 3: Qualitative Assessment Low investment level: Here Embla deviates, as bionics requires ongoing R&D (approx. 5% of revenue). Mergers/Acquisitions: Embla makes "bolt-on" acquisitions, where they buy smaller clinics and roll out their own technology in them (synergy effect). Løgstrup is mostly against large "headless" acquisitions, where a company buys a competitor that is almost as large as themselves. It is part of their core strategy to own the entire value chain. Stable management: The company is known for very experienced management with a long-term perspective, supported by the ultra-conservative main owner, William Demant Invest. High distribution: Embla does not pay high dividends, but instead uses share buybacks. Løgstrup often sees buybacks as a "tax-efficient dividend payment", especially when the price is low. Focused company: Yes, they do only one thing: Mobility solutions. No "diworsification". Among the best: They are undisputed top-2 in the world. Low risk during economic downturn: Here Embla scores top marks. People do not stop needing prostheses just because there is a crisis. It is a defensive growth stock. Conclusion: Embla Medical meets most of his criteria: It is a focused market leader in a defensive industry, currently trading at a reasonable price due to temporary headwinds (tariffs/currency).It's a good analysis that also reflects why I own the stock. Furthermore, Embla expects 5-7% organic growth and not 7-9% as stated in the analysis. That makes a big difference in the valuation. There are some seemingly very stable shareholders in the company, including demant holding and ATP, and the share of institutional investors is around 71%. This also means that there are relatively few private investors in the stock, which can also be seen from the interest here. It should make the share buyback program more effective that so many shares are held stably by the large investors, but unfortunately, the program is so small that the effect is probably limited. By the way, I don't think Løgstrup himself owns the stock. He seems to be focused on stocks with lower PE, such as banks, ISS, etc.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt